Early fibrinogen concentrate therapy for major haemorrhage in trauma (E-FIT 1): results from a UK multi-centre, randomised, double blind, placebo-controlled pilot trial

Table 3 Transfusion requirements during the first 24 hours

	Fibrinogen concentrate arm (n = 24)	Placebo arm (n = 24)	p Value
Units at 3 h
RBC	4 (2–6)	2 (2–6)	0.73
FFP	3 (2–6)	3 (0–7)	0.92
Platelets	0 (0–1)	0 (0–1)	0.98
Cryoprecipitate	0 (0–2)	0 (0–1)	0.46
Units at 6 h
RBC	3 (2–6)	2 (2–5)	0.62
FFP	4 (2–6)	3 (0–7)	0.77
Platelets	0 (0–1)	0 (0–1)	0.85
Cryoprecipitate	0 (0–2)	0 (0–0)	0.12
Units at 24 h
RBC	4 (2–8)	2 (2–5)	0.38
FFP	5 (2–8)	3 (0–6)	0.39
Platelets	1 (0–1)	0 (0–1)	0.59
Cryoprecipitate	2 (0–2)	0 (0–0)	0.06

FFP Fresh frozen plasma, RBC Red blood cells
Data are median (IQR). At each time point blood component use was analysed for patients who were still alive within the specified time frame. One participant died within 2 h (± 30 min) of admission, two within 3 h (± 30 min) of admission, five within 6 h (± 1 h) of admission and seven within 24 h (± 4 h) of admission

ISSN: 1364-8535